The African Malaria Partnership (AMP) was established in 2001 to improve the prevention and treatment of malaria in sub-Saharan Africa. Since then, GlaxoSmithKline (GSK) has committed over $3 million on initiatives to combat the disease. Initial activities focused on behavioral change programs across eight African countries aimed at l to encouraging people to sleep under treated bed nets and seek treatment for children with a fever.
The AMP has also contributed to initiatives aimed at generating greater awareness, political commitment and sustained funding to combat the disease were it has been implemented. National Coalitions Against Malaria have now been launched in the UK, Belgium, France, Ethiopia, Cameroon and Mozambique.
Finally, the AMP has made a commitment of over $1.5 million to be spent over a period spanning three years with partnerships in four African countries. With a focus on working with building capacity of community health workers and creating behavior change the AMP is dedicated to seeing an end to the Malaria Epidemic.
The AMP has contributed to a 40% reduction in Malaria associated reduce morbidity and mortality where implemented by improving community level prevention of malaria and increasing access to health services and by targeting aid to the most vulnerable: women, children under five, people living with HIV/AIDS and young people.